RNS Number:4948H
Oxford Technology Vent Cap Tst PLC
17 March 2000

                 
Oxford Technology VCT has invested a further #24,996 for 2,083 ordinary shares
in Avidex Ltd. This investment brings OTVCT's total percentage equity to about
15.5%.

The company is a spin out from the University of Oxford and is led by Dr
Jakobsen, who is head of the T Cell Receptor Group at the Institute of Molecular
Medicine. The company is working in two primary areas, the use of engineered CD8
as an inhibitor of various auto-immune diseases such as rheumatoid arthritis,
and the use of engineered, soluble T Cell receptors to target drugs. Since
making the initial investment, it has become apparent that the fundamental
technology has even wider application than originally realised and additional
patents have been filed.

For further information, please contact Oxford Technology VCT on 01865 784466.


END
MSCJRMJTMMJBBLM
Oxford Technology Ventur... (LSE:OXT)
Historical Stock Chart
From Jul 2024 to Jul 2024 Click Here for more Oxford Technology Ventur... Charts.
Oxford Technology Ventur... (LSE:OXT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Oxford Technology Ventur... Charts.